Results 261 to 270 of about 268,538 (298)
Some of the next articles are maybe not open access.
Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors.
Current pharmaceutical design, 2015The renin-angiotensin system has been established as an attractive target for pharmacological intervention since the discovery of first angiotensin-converting enzyme inhibitors (ACE-Is).
M. Regulski +6 more
semanticscholar +1 more source
Angiotensin-converting enzyme inhibitors in the elderly
American Heart Journal, 1989Although early studies suggested little role for angiotensin-converting enzyme (ACE) inhibitors in older hypertensive patients, more careful evaluation has confirmed their efficacy and good tolerability. Although the elderly tend to have low plasma renin levels, the fall in blood pressure after ACE inhibitors is at least as great (and in several ...
Kennedy R. Lees +3 more
openaire +3 more sources
Angiotensin-Converting Enzyme Inhibitor Angioedema
The Journal of Emergency Medicine, 2012*Department of Emergency Medicine, University of Michigan/St. Joseph Mercy Emergency Medicine Residency, Ann Arbor, Michigan, and †Department of Emergency Medicine, University of Michigan Health System, Ann Arbor, Michigan Reprint Address:Michaelina R. Bolton, MD, Department of Emergency Medicine, University of Michigan Health System, 1500 E.
Suzanne Dooley-Hash, M Bolton
openaire +3 more sources
Angiotensin-Converting Enzyme Inhibitor Angioedema
Advanced Emergency Nursing Journal, 2020Angioedema from angiotensin-converting enzyme inhibitors (ACEIs) is a potential, emergent, and frightening problem that presents to the emergency department. This article focuses on angioedema caused by using ACEIs. The presentation, pathology, diagnostic testing, treatment, and patient education of angioedema are explored.
Josh Bankston, David Thomas House
openaire +2 more sources
Angiotensin-Converting Enzyme Inhibitors
2000Angiotensin-converting enzyme (ACE) inhibitors have been available for more than a decade for clinical use to treat hypertension and congestive heart failure (CHI). An intravenous agent, enalaprilat, has been approved by the Food and Drug Administration (FDA) for use in hypertension, and ten oral agents—benazepril, captopril, enalapril, fosinopril ...
Angela Cheng-Lai +2 more
openaire +2 more sources
Angiotensin Converting Enzyme Inhibitors and Cough
Journal of Cardiovascular Pharmacology, 1989Angiotensin converting enzyme (ACE) inhibitors produce a dry, nonproductive cough in some patients. Retrospective surveys have suggested an incidence of cough of between 0.7 and 14%. Those patients who develop cough show a marked increase in the sensitivity of the cough reflex to inhalation of the extract of red pepper, capsaicin.
R W Fuller, J R McEwan
openaire +3 more sources
New England Journal of Medicine, 2000
BACKGROUND Angiotensin-converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure.
S. Yusuf +5 more
semanticscholar +1 more source
BACKGROUND Angiotensin-converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure.
S. Yusuf +5 more
semanticscholar +1 more source
Angiotensin Converting Enzyme Inhibitors
1999The synthesis of the first orally active angiotensin converting enzyme (ACE) inhibitor in the 1977, heralded one of the major therapeutic advances of the last decades. Initially designed to be a pathophysiological meaningful tool for the treatment of severe malignant hypertension, ACE inhibitors are now widely accepted as first line approach to the ...
openaire +2 more sources
Angiotensin-Converting Enzyme (ACE) Inhibitors
2015Angiotensin converting enzyme inhibitors represent a new class of agents which were designed to retain only that unique property. Because of this inhibition, administration of these agents results in the significant reduction of elevated blood pressure of various etiologies and in the amelioration of symptoms associated with congestive heart failure ...
Daniel Thomas Ginat, Jason M. Johnson
openaire +2 more sources
Oral angiotensin-converting-enzyme inhibitors
American Journal of Health-System Pharmacy, 1997The pharmacology, pharmacokinetics, clinical uses, adverse effects, drug interactions, dosage, cost, and therapeutic interchange of oral angiotension-converting-enzyme (ACE) inhibitors are reviewed. ACE inhibitors attenuate the formation of angiotension II and may lead to the accumulation of kinins.
openaire +2 more sources